Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded by Truist Financial to “Strong-Buy” Rating

Truist Financial upgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX) to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Other research analysts also recently issued reports about the company. Oppenheimer lifted their target price on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday, March 10th. Barclays increased their price target on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the company an “overweight” rating in a research note on Tuesday, February 17th. Canaccord Genuity Group raised their price objective on Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research report on Tuesday, February 17th. Bank of America lifted their price objective on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Finally, Jefferies Financial Group started coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, March 10th. They set a “buy” rating and a $580.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $554.30.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $454.97 on Wednesday. The company has a fifty day moving average price of $468.97 and a 200-day moving average price of $441.56. The company has a market capitalization of $115.58 billion, a P/E ratio of 29.68, a PEG ratio of 1.92 and a beta of 0.31. Vertex Pharmaceuticals has a 52-week low of $362.50 and a 52-week high of $510.77.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.Vertex Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.98 EPS. As a group, sell-side analysts forecast that Vertex Pharmaceuticals will post 15.63 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the transaction, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. This trade represents a 21.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Amit Sachdev sold 1,846 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $897,802.10. Following the completion of the transaction, the executive vice president directly owned 55,570 shares in the company, valued at $27,026,469.50. This represents a 3.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 93,485 shares of company stock worth $43,967,586. 0.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Vertex Pharmaceuticals by 3.8% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock worth $213,435,000 after purchasing an additional 20,053 shares during the period. Leuthold Group LLC acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $5,030,000. Danske Bank A S acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $64,417,000. Advisory Resource Group bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $1,286,000. Finally, Generali Asset Management SPA SGR boosted its position in shares of Vertex Pharmaceuticals by 41.8% during the 3rd quarter. Generali Asset Management SPA SGR now owns 23,569 shares of the pharmaceutical company’s stock worth $9,231,000 after purchasing an additional 6,942 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Truist raised its price target on Vertex to $525 (from $490) and kept a Buy rating after encouraging Week‑36 interim results from Vertex’s Phase 3 RAINIER study — a clear positive catalyst supporting higher upside expectations. Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results
• Positive Sentiment: Multiple bullish writeups and retail/investor attention argue VRTX remains a buy—analysts and commentators point to durable CFTR franchise cash flows, pipeline upside and the recent dip as a potential buying opportunity. Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?
• Neutral Sentiment: Zacks and market headlines note VRTX outperformed the broader market in the latest session and is drawing elevated attention from Zacks users — this likely amplified buying interest but is descriptive rather than a fresh fundamental shift. Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Reports of large short‑interest changes are inconsistent/placeholder in recent feeds (reported zeros/NaN), so there’s no clear short‑squeeze signal — effectively neutral on near‑term price pressure.
• Negative Sentiment: Competition risk: Maze Therapeutics reported positive Phase II data for an APOL1‑mediated kidney disease drug that targets the same pathway Vertex is pursuing — the news highlights competitive risk to Vertex’s AMKD franchise, which could weigh on long‑term upside if competitors advance. Maze tumbles despite positive data for kidney disease drug

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.